Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC32H48BrN3O4 |
InChIKeyLBFDLJSQMPCWKK-YMNKQYQVSA-N |
CAS Registry1817841-22-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 28 Apr 2022 |